Up
2003P-0365:GALDERMA
PRODUCT, SOLAGE CONTAINING 2% MEQUINOL, AND 0.01% TRETINOIN, NDA
20-922 CAN BE FORMULATED AS A TOPICAL SOLUTION WITH THE SUBSTITUTION
OF HYDROQUINONE AT 4% FOR THE 2% MEQUINOL AS AN ANDA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Document #
|
| Received Date
|
| Filed
Date
|
| Submitter Code
|
| Submitter
|
| FR
Date
|
| FR
Page
|
| Comment Date
|
| Files
|
| Remarks
|
|
|
|
|
| CP1
|
| 08/12/2003
|
| 08/13/2003
|
| Private
Industry
|
| Jerussi
Consulting, Inc.
|
|
|
|
|
|
|
| pdf,
Copyrighted
Material
|
|
|
|
| Signature:
|
| Robert A. Jerussi,
Ph.D.
|
|
|
| ACK1
|
| 08/13/2003
|
| 08/13/2003
|
| Federal
Government
|
| HFA-305
to Jerussi Consulting, Inc.
|
|
|
|
|
|
|
| pdf,
doc
|
|
|
|
|
| Signature:
|
| Lyle D. Jaffe
|
|
|
|
|
| C1
|
| 11/14/2003
|
| 11/14/2003
|
| Drug Industry
|
| Galderma
Laboratories
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
| Signature:
|
| Paul Clark
|
|
| C2
|
| 01/16/2004
|
| 01/16/2004
|
| Private
Industry
|
| Jerussi
Consulting, Inc.
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
| Signature:
|
| Robert A. Jerussi,
PhD
|
|
| LET1
|
| 02/05/2004
|
| 02/05/2004
|
| Federal
Government
|
| HFD-600
to Jerussi Consulting Inc
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
|
|
| Signature:
|
| Gary Buehler
|
|
|
| LET2
|
| 03/30/2004
|
| 03/30/2004
|
| Private
Industry
|
| Jerussi
Consulting, Inc.
|
|
|
|
|
|
|
| pdf
|
|
|
|
| Signature:
|
| Robert A. Jerussi,
PhD
|
|
|
| PDN1
|
| 10/19/2004
|
| 10/19/2004
|
| Federal
Government
|
| HFD-600
to Jerussi Consulting, Inc.
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
| Signature:
|
| Gary J. Buehler
|
|
|
|
|
| LET3
|
| 11/12/2004
|
| 11/12/2004
|
| Private
Industry
|
| Jerussi
Consulting, Inc.
|
|
|
|
|
|
|
| pdf
|
|
|
|
| Signature:
|
| Robert A. Jerussi,
PhD
|
|
|
| PDN2
|
| 12/03/2004
|
| 12/03/2004
|
| Federal
Government
|
| HFD-600
to Jerussi Consulting, Inc.
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
| Signature:
|
| Gary J. Buehler
|
|
| |
Top | Up
Page last updated
December 30, 2004
kk |